Peptide Drug Interactions: What Not to Use With Peptides

Before You Begin: Safety and Supervision

Drug interaction data for peptide compounds vary enormously by compound class. FDA-approved peptides such as semaglutide and bremelanotide have published pharmacokinetic studies that characterize interactions with common co-medications. Most research peptides have no formal human interaction studies at all — their interaction profiles are essentially unknown. This gap means that a licensed prescribing provider who knows your full medication list is the appropriate person to assess interaction risk for your specific protocol, not a general-audience article. The information below covers what the published evidence shows for each major peptide class. It is educational context for that clinical conversation, not a substitute for it.

What You Will Need for a Safe Peptide Protocol

Managing interaction risk in a peptide protocol requires complete information at the outset. Before your first injection, your provider and care team need:

• A complete medication list: Every prescription drug, including dose and frequency. For GLP-1 receptor agonists in particular, oral medications with narrow therapeutic indices require specific pharmacokinetic attention.
• A complete supplement list: Vitamins, minerals, herbals, and over-the-counter products. Supplement-peptide interactions are largely unstudied but can affect the physiological environment of the protocol.
• Relevant baseline labs: Liver enzymes, kidney function, fasting glucose, and thyroid function where applicable. These establish safety baselines relevant to both the peptide and potential interactions with co-medications.
• Any supplies specified by your provider or compounding pharmacy: Follow your prescriber's instructions exactly regarding vials, syringes, and reconstitution materials.

If you are sourcing a peptide from a non-provider channel, be aware that product quality cannot be assumed. The 2026 FAERS pharmacovigilance analysis by McCall and colleagues in Expert Opinion on Drug Safety documented higher adverse event rates for compounded versus branded GLP-1 receptor agonists.

How Peptide Drug Interactions Work: A Framework

Your provider will apply the following principles to your specific medication list. The description below explains why peptide interactions are different from most drug-drug interactions and where specific risks exist.

1. Disclose everything to your provider before starting: The foundation of safe co-administration is a complete medication and supplement inventory. Peptide interactions that matter are often pharmacodynamic rather than pharmacokinetic — which means they may not show up in standard drug interaction checkers that focus on CYP450 pathways. Follow your provider's instructions exactly regarding timing of co-medications and any adjustments needed.
2. Understand the CYP450 difference: Most peptides are broken down by proteases and eliminated renally rather than by cytochrome P450 liver enzymes. This is why classical drug-drug interaction concerns are fewer for peptides than for most small-molecule drugs. However, pharmacodynamic interactions — where one compound changes the biological environment in which another operates — still apply and are compound-specific.
3. Pay specific attention to oral drug timing with GLP-1 agonists: GLP-1 receptor agonists delay gastric emptying. This affects when orally administered drugs reach the small intestine for absorption. For most medications the delay is modest and not expected to produce clinically meaningful changes, though Cmax and tmax shifts have been documented. For narrow-therapeutic-index drugs — those where small changes in blood concentration have large clinical consequences — the delay can be meaningful. Your provider will advise on any specific adjustments needed.
4. For GHRH analogs: monitor glucose if applicable: GH-axis activation through GHRH analogs can impair insulin sensitivity. For patients with diabetes or prediabetes, glucose monitoring is typically recommended during GHRH analog therapy per the tesamorelin prescribing information and standard endocrine practice. Falutz and colleagues, in the tesamorelin registration trial published in the New England Journal of Medicine in 2007, reported changes in glucose tolerance warranting monitoring in patients with diabetes. Your provider will order appropriate glucose monitoring as part of your protocol.
5. For melanocortin peptides: blood pressure is the priority: Bremelanotide (Vyleesi) raises blood pressure transiently. Concomitant antihypertensive use requires monitoring. The compound is contraindicated in uncontrolled hypertension per its FDA-approved prescribing information. Your provider will confirm blood pressure stability before prescribing.
6. For research peptides (BPC-157, TB-500, and similar compounds classified as FDA Category 2 bulks or otherwise not compoundable under § 503A): assume unknown interaction profile. A 2025 review in Pharmaceuticals (Basel) documented that BPC-157 human safety evidence remains limited. These compounds are not available through licensed U.S. compounding pharmacies and have no FDA-approved human use; use outside an IRB-approved investigational research protocol lacks a clear regulatory pathway under current FDA policy. If a product marketed as BPC-157 or TB-500 was obtained through a non-pharmacy channel, its concentration, purity, and identity cannot be assumed to match the label; analyses of non-prescription peptide products have documented dose inaccuracies, misidentified compounds, and contaminants — which compounds any theoretical interaction risk with an unknown-composition risk.

GLP-1 Receptor Agonists: What the Interaction Data Show

Gastric emptying delay and oral drug absorption

The defining pharmacokinetic feature of GLP-1 receptor agonists relevant to drug interactions is delayed gastric emptying. A 2024 systematic review and meta-analysis by Hiramoto and colleagues in the American Journal of Gastroenterology quantified GLP-1 agonist-induced gastric emptying delay at approximately 36 minutes on average — modest in absolute terms but clinically meaningful for drugs where absorption timing affects efficacy or safety. A 2025 physiologically-based pharmacokinetic (PBPK) modeling analysis by Hooper and colleagues in Pharmacotherapy predicted that GLP-1 receptor agonist-induced delays in gastric emptying could produce clinically meaningful effects on co-administered drug absorption, with the largest impact on narrow-therapeutic-index oral medications. A 2024 systematic review by Calvarysky and colleagues in Drug Safety characterized GLP-1 receptor agonist interactions with oral medications across the published literature, finding consistent evidence of delayed but not reduced absorption for most co-administered drugs.

Specific co-medications with published data

For injectable semaglutide, Hausner and colleagues published a dedicated pharmacokinetic interaction study in Clinical Pharmacokinetics in 2017, finding no meaningful alteration of metformin, warfarin, atorvastatin, or digoxin pharmacokinetics in healthy subjects. For oral semaglutide, Bækdal and colleagues published a 2019 study showing increased metformin AUC by 32% — attributed to extended gastric residence time with the oral formulation's SNAC absorption-enhancing mechanism. Oral semaglutide does not affect oral contraceptive (ethinylestradiol/levonorgestrel) pharmacokinetics, per a dedicated study by Jordy and colleagues published in Clinical Pharmacokinetics in 2021. The levothyroxine interaction identified in a 2021 pharmacokinetic study published in Expert Opinion on Drug Metabolism and Toxicology (PMID 34289755) is specific to oral semaglutide and is reflected in the FDA-approved Rybelsus prescribing information, which recommends thyroid monitoring in co-administered patients.

Absolute contraindications for GLP-1 receptor agonists

Smits and van Raalte, in their 2021 safety review of semaglutide published in Frontiers in Endocrinology, summarized the key contraindications: a personal or family history of medullary thyroid carcinoma (MTC), and multiple endocrine neoplasia syndrome type 2 (MEN2). These are absolute contraindications based on rodent carcinogenicity data and their designation in the FDA-approved prescribing information. Biliary disease risk is an additional signal that warrants monitoring in susceptible patients. These exclusions apply to the FDA-approved products; discuss with your provider how they apply to your individual health history.

GHRH Analogs: Metabolic Monitoring and Interactions

Glucose and insulin sensitivity

GHRH analogs stimulate endogenous GH release. GH is a counter-regulatory hormone that can impair insulin sensitivity, particularly at higher GH activity levels. Falutz and colleagues, in the tesamorelin registration trial published in the New England Journal of Medicine in 2007, reported changes in glucose tolerance warranting monitoring in patients with diabetes. Stanley and colleagues reported improvements in liver fat with tesamorelin in HIV-associated lipodystrophy; hepatic monitoring is standard in any population with hepatotoxic co-medications. For patients with type 2 diabetes, prediabetes, or impaired fasting glucose, GHRH analog protocols require closer metabolic monitoring — a direct pharmacodynamic interaction with the glucose-regulating medications they may already be taking.

Insulin and antidiabetic drugs

GH-axis activation can partially antagonize insulin action. Patients on insulin or oral antidiabetic medications starting a GHRH analog protocol require monitoring of fasting glucose and HbA1c at baseline and at regular intervals. Antidiabetic drug doses may require adjustment under provider supervision. Do not modify antidiabetic doses without consulting your provider.

Melanocortin Peptides (Bremelanotide / PT-141): Blood Pressure and Contraindications

Bremelanotide (FDA-approved as Vyleesi for hypoactive sexual desire disorder in 2019) has the most clearly documented interaction profile among the melanocortin-class peptides. The FDA-approved Vyleesi prescribing information contraindicates concomitant use with uncontrolled hypertension and requires blood pressure monitoring. Rosen and colleagues documented transient blood pressure elevation as a pharmacological effect of bremelanotide in a 2004 International Journal of Impotence Research study (PMID 14999221) in an earlier compound development context; Clayton, Kingsberg, and colleagues confirmed blood pressure monitoring requirements in the Vyleesi phase-3 program reported in the Journal of Women's Health in 2022 (PMID 35147466). Per bremelanotide's FDA-approved prescribing information (dailymed.nlm.nih.gov), concomitant use with oral naltrexone may significantly reduce naltrexone absorption and is not recommended in patients taking oral naltrexone for opioid or alcohol use disorder. Patients on antihypertensive therapy who are prescribed bremelanotide require blood pressure monitoring as part of their protocol.

Research Peptides: What Is Not Known

The interaction profile of research peptides is the area of greatest uncertainty. A 2025 review in Pharmaceuticals (Basel) on BPC-157 documented that the peptide has not been approved by the FDA or other global regulatory authorities due to the absence of sufficient and comprehensive human clinical studies, and no formal drug-interaction data have been published for this compound. A 2025 systematic review by Vasireddi and colleagues in the HSS Journal flagged contamination and unknown-interaction risks from unregulated BPC-157 sources as primary concerns. A 2025 immunogenicity assessment review by Achilleos and colleagues in the Journal of Peptide Science noted that novel or compounded peptides carry unpredictable immune-reaction risks. The 2026 FAERS pharmacovigilance analysis by McCall and colleagues in Expert Opinion on Drug Safety documented higher odds of adverse events and product-quality issues for compounded GLP-1 receptor agonists compared to branded products — a pattern that extends to research peptides from non-pharmacy-grade sources.

For anyone using research peptides, the practical implication is: assume the interaction profile is unknown, disclose all co-medications to your provider, and do not layer research peptides onto other compounds without clinical oversight.

Context for compounded GLP-1 receptor agonists: the 2022–2024 FDA-declared shortages of semaglutide and tirzepatide closed in late 2024 and early 2025, ending the broad 503A/503B enforcement-discretion pathway under which many compounded GLP-1 products were dispensed. As of April 2026, compounded semaglutide and tirzepatide are legally available only under the narrow § 503A patient-specific clinical-difference pathway. Products obtained outside this pathway are not covered by FDA enforcement discretion and carry additional quality uncertainty.

Peptides and AAS Stacking: An Evidence Gap

Combining GHRH analogs or GH-releasing peptides with anabolic-androgenic steroids occurs in performance contexts but lacks formal safety or interaction data. Rahnema and colleagues, in their 2014 Fertility and Sterility review, documented the endocrine disruption profile of AAS use independently — including HPG axis suppression and cardiovascular risk. Adding GH secretagogue compounds to this context introduces pharmacological variables whose interactions have not been studied in controlled settings. This combination is outside the scope of any adequate and well-controlled clinical trial, and no approved indication supports it.

Storage, Handling, and Disposal

Your prescribing provider or compounding pharmacy will provide storage, handling, and disposal instructions specific to your compound. Follow those instructions exactly.

Common Issues and Troubleshooting

• New medication added after starting peptide protocol: Contact your prescribing provider before starting any new medication — prescription or over-the-counter — while on a peptide protocol. For GLP-1 agonists, new oral medications with narrow therapeutic indices require specific timing guidance.
• Unexpected blood pressure change on melanocortin peptide: Contact your provider immediately. Do not self-adjust antihypertensive doses.
• Unexplained glucose variability on GHRH analog protocol: Increase monitoring frequency and contact your provider. Do not self-adjust insulin or antidiabetic doses without clinical guidance.
• Concerns about research peptide interactions: The honest answer for most research peptides is that interaction data do not exist. Your provider can apply pharmacological reasoning and your specific health context to assess risk — which is a different, more valuable input than community-sourced guidance.

When to Contact Your Provider

• Before starting any new medication while on a peptide protocol
• Any unexpected change in blood pressure, glucose levels, or thyroid function parameters during a peptide course
• Any new symptom that begins within days of starting or changing a peptide protocol
• Signs of allergic or immune reaction: rash, itching, swelling, or difficulty breathing following injection

Seek emergency care for signs of anaphylaxis: throat tightening, difficulty breathing, severe widespread hives, or loss of consciousness following injection.

Understanding Your Baseline Before Starting

Before starting any peptide protocol — particularly one where interactions with existing medications are a consideration — baseline labs provide the clinical reference points that make monitoring meaningful. Liver enzymes including alanine aminotransferase (ALT) establish hepatic function before adding any compound with hepatic processing considerations. Kidney function via eGFR is relevant because most peptides are renally cleared, and impaired renal function alters pharmacokinetics for the peptide itself. Fasting glucose and HbA1c establish the metabolic baseline relevant to GHRH analog glucose monitoring requirements. That principle — establish a measured baseline before any intervention, then interpret changes in context — is central to Superpower's approach to preventive health.

IMPORTANT SAFETY INFORMATION

The information on this page is educational and does not constitute medical advice, a diagnosis, or a treatment recommendation. Peptide drug interactions vary substantially by compound class. FDA-approved peptides have published pharmacokinetic interaction data; research peptides have little to none. Do not use this page to self-assess interaction risk — your prescribing provider, who has your complete medication history, is the appropriate resource for that evaluation.

Always disclose all current medications, supplements, and health conditions to your prescribing provider before starting any peptide protocol. Drug interaction profiles described on this page reflect published literature as of April 2026. New interaction data may be published after this date.

Compounded peptides are not FDA-approved drug products. Products obtained outside licensed pharmacy channels may not match their labeled concentration or purity. Compounded peptide products may carry higher adverse event rates than FDA-approved branded formulations due to the absence of FDA premarket approval and variable manufacturing oversight.

Any peptide prescribed in connection with Superpower's platform is prescribed at the independent clinical discretion of a licensed healthcare provider. All medication and supplement co-administration decisions are made by your provider in the context of your individual health history.

Disclaimer: IMPORTANT: The information on this page describes peptide drug interactions as an educational reference. It does not constitute medical advice and does not replace assessment by a licensed healthcare provider who knows your complete medication list. Any peptide prescribed in connection with Superpower's platform is prescribed at the independent clinical discretion of a licensed healthcare provider. Always disclose all medications and supplements to your care team before starting any peptide protocol.